PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI) (the “Company”), a medical device and pharmaceutical company focused on advanced wound care, today announced that it closed an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share on April 5, 2012. The Company plans to use the approximately $17.9 million in net proceeds for the continued development of DSC127 and for general corporate purposes.
